<DOC>
	<DOCNO>NCT00004182</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient metastatic recurrent breast cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Metastatic Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate irinotecan patient metastatic breast cancer receive prior anthracycline taxane base chemotherapy metastatic disease . II . Determine toxicity irinotecan patient . III . Determine survival time , duration response , time treatment failure patient therapy . OUTLINE : Patients receive irinotecan IV 90 minute weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients follow day 30 , every 3 month . PROJECTED ACCRUAL : A total 14-29 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced breast cancer Must receive anthracycline taxane base chemotherapy metastatic disease Measurable disease No CNS metastases carcinomatous meningitis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Granulocyte count great 1500/mm3 Hemoglobin least 9.0 g/dL Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.3 mg/dL SGOT great 3 time upper limit normal ( great 5 time ULN liver involvement ) No Gilbert 's disease Renal : Creatinine great 2.0 mg/dL Calcium least 12.0 mg/dL Cardiovascular : No myocardial infarction past 6 month No congestive heart failure require therapy Other : No active uncontrolled infection HIV negative No psychiatric disorder would preclude study No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No history seizures No uncontrolled diabetes mellitus ( random blood sugar least 200 mg ) No severe disease would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Greater 4 week since prior chemotherapy No prior irinotecan topotecan Endocrine therapy : Not specify Radiotherapy : Greater 4 week since prior radiotherapy No radiotherapy great 30 % bone marrow Surgery : Not specify Other : No concurrent phenytoin , phenobarbitol , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>